DLB N = 67 | AD N = 65 | AD+DLB N = 13 | |||||||||||
Pro-DLB N = 51 | DLB-d N = 16 | Pro-AD N = 33 | AD-d N = 32 | Pro-AD/DLB N = 2 | AD/DLB-d N = 11 | CSf N = 21 | Test statistic, P | Post hocg | |||||
Age, yearsa | 66.2 (9.0) | 75.4 (7.0) | 71.1 (8.0) | 70.8 (8.2) | 77.5 (4.9) | 77.3 (6.3) | 68.5 (9.0) | H = 19.88, P = .0013 | Pro-DLB < DLB-d and AD/DLB-d P < 0.05 | ||||
Gender (F/M) | 27/24 | 12/4 | 15/18 | 20/12 | 1/1 | 6/5 | 11/10 | χ2 = 4.677, P = .4566 | |||||
MMSE scoreb | 27.3 (2.4) | 21.0 (4.0) (1ND) | 26.4 (2.7) | 21.4 (4.3) | 26.5 (2.1) | 20.7 (3.4) | 26.9 (2.3) | H = 80.34, P < .0001 | Pro and CS > d | ||||
Hallucinationsc, i | 68.6% | 56.3% | 12.5% (1ND) | 32.3% (1ND) | 50% | 63.6% | 33.3% | χ2 = 29.99 P < .0001 | |||||
Fluctuationsc, j | 83.3% (3ND) | 75.0% | 9.7% (2ND) | 38.7% (1ND) | 100% | 90.9% | 38.1% | χ2 = 55.04, P < .0001 | |||||
Parkinsonism | Rigidity 0/1/2/3/4 | 24/29/1/0/0 (2ND) | 3/7/5/1/0 | 27/5/1/0/0 | 23/8/1/0/0 | 0/2/0/0/0 | 2/9/0/0/0 | 11/8/0/2/0 | H = 37.99, P < .0001 | pro-DLB > pro-AD and AD-d; DLB-d > pro-AD and AD-d; AD/DLB-d > pro-AD | |||
Akinesia 0/1/2/3/4 | 22/22/6/0/0 (2ND) | 3/8/3/2/0 | 29/4/0/0/0 | 27/4/1/0/0 | 0/2/0/0/0 | 2/7/1/1/0 | 17/2/2/0/0 | H = 46.15, P < .0001 | CS < DLB-d and AD/DLB-d; pro-DLB > pro-AD and AD-d; DLB-d and AD/DLB-d > pro-AD and AD-d | ||||
Tremor at rest 0/1/2/3/4 | 32/15/1/0/0 (3ND) | 11/5/0/0/0 | 30/3/0/0/0 | 30/1/0/0/0 (1ND) | 1/1/0/0/0 | 9/2/0/0/0 | 19/2/0/0/0 | H = 16.87, P < .0048 | Pro-DLB > AD-d | ||||
RBDc, k | 43.8% (3ND) | 43.8% | 6.1% | 19.4% (1ND) | 0% | 27.3% | 33.3% | χ2 = 16.99, P = .00045 | |||||
Hippocampi atrophyd 0/1/2/3/4 | Left hippocampus | 23/15/6/5/1 (1ND) | 1/4/7/1/3 | 3/19/8/2/0 (1ND) | 5/9/12/2/1 (3ND) | 1/0/0/1/0 | 0/6/4/0/1 | 10/4/4/2/0 (1ND) | H = 21.00, P = .0008 | DLB-d > CS and pro-DLB | |||
Right hippocampus | 23/17/8/1/1 (1ND) | 2/6/3/1/4 | 5/18/8/1/0 (1ND) | 7/12/8/1/1 (3ND) | 1/0/0/1/0 | 0/6/4/0/1 | 8/6/6/0/0 (1ND) | H = 16.68, P = .0051 | |||||
FCSRTe | 22% (1ND) | 71.4% (2ND) | 78.1% (1ND) | 93.5% (1ND) | 50% | 100% (1ND) | 30.0% (1ND) | χ2 = 62.7, P < .0001 | |||||
CSF biomarkersh | t-Tau (ng/L) | 271 [108] | 306 [108] | 630 [339] | 628 [231] | 582 [486] | 627 [307] | 265 [93] | H = 88.14 P < .0001 | CS, pro-DLB, DLB-d < pro-AD, AD-d, AD+DLB-d | |||
P-Tau (ng/L) | 43 [15] | 47 [14] | 91 [33] | 81 [22] | 76 [58] | 92 [44] | 43 [17] | H = 90.34 P < .0001 | CS, pro-DLB, DLB-d < pro-AD, AD-d, AD+DLB-d | ||||
Aβ42 (ng/L) | 911 [292] | 742 [268] | 642 [299] | 518 [571] | 688 [194] | 437 [181] | 1002 [256] | H = 59.30 P < .0001 | CS, pro-DLB > pro-AD, AD-d, AD+DLB-d | ||||
t-α-synuclein | 118 [49] | 112 [62] | 197 [77] | 183 [114] | 145 [29] | 187 [86] | 141 [57] | H = 35.55 P < .0001 | Pro-DLB < pro-AD and AD-d; DLB-d < pro-AD | ||||
Aβ40 assays | DLB N = 34 | AD N = 25 | AD+DLB N = 6 | ||||||||||
Pro-DLB N = 28 | DLB-d N = 6 | Pro-AD N = 16 | AD-d N = 9 | Pro-AD/DLB N = 1 | AD/DLB-d N = 5 | CSf N = 11 | |||||||
Aβ40 (ng/L) | 9081 [2320] | 8303 [2681] | 13,892 [6575] | 10,293 [3891] | 22,700 | 12,423 [4468] | 11,308 [4825] | H = 10.08 P = 0.0731 | |||||
Aβ42/Aβ40 | 0.107 [0.035] | 0.107 [0.048] | 0.052 [0.021] | 0.051 [0.022] | 0.036 | 0.039 [0.005] | 0.102 [0.029] | H = 42.13 P < .0001 | CS and pro-DLB > pro-AD, AD-d, AD+DLB-d; DLB-d > AD+DLB-d |